Precision cancer diagnostics through tissue processing and digital pathology
Epredia manufactures tissue processing systems, microscope slides, and staining reagents for anatomical pathology labs, with products deployed over a billion times annually across hospital and research pathways. The tech stack reveals a mature enterprise operation—Salesforce, SAP, PostgreSQL, and HL7/DICOM/SNOMED integrations—anchored in regulatory compliance (IEC 62304, ISO 13485). Active projects around AI-driven image management and digital slide format conversion signal a shift toward computational pathology, though pain points around format interoperability and LIS integration suggest the market is still fragmenting on data standards.
Epredia is a global precision cancer diagnostics company based in Portsmouth, New Hampshire, operating under PHC Group ownership since 2019. The company manufactures a suite of specialized products for anatomical pathology: tissue processing equipment (Microm, Shandon brands), embedding media, microscope slides (Menzel Gläser, Richard-Allan Scientific), and staining systems. The organization spans 1,001–5,000 employees across manufacturing, engineering, and support-heavy operations in the United States, Germany, China, Netherlands, and United Kingdom. Revenue derives from consumables and capital equipment sold into hospital laboratories, diagnostic centers, and research institutions—a recurring-revenue model given the volume-based customer engagement.
Core stack includes Salesforce (CRM), SAP (ERP), PostgreSQL (database), C# and .NET (backend), React (frontend), and regulatory/medical standards like HL7, DICOM, SNOMED, IEC 62304, ISO 13485.
Yes—integrating AI-driven capabilities into image management and digital pathology systems are active projects. Challenges include converting between digital slide formats and maintaining interoperability with laboratory information systems.
Other companies in the same industry, closest in size